EGFR+ Lung Cancer

The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.

Osimertinib was associated with a 47% reduction in risk of death among patients with stage II-IIIA EGFR-mutated non–small cell lung cancer at 8 years.

First-line amivantamab plus chemotherapy produced the longest reported median OS in EGFR exon 20 insertion-positive advanced NSCLC in the phase 3 PAPILLON trial.

Phase 3 SANOVO shows savolitinib plus osimertinib extends PFS in first-line EGFR-mutant, MET-high NSCLC, hinting at OS gains.

The FDA has granted fast track designation to BH-30643, an oral OMNI-EGFR inhibitor, for advanced EGFR C797S-positive non–small cell lung cancer after a third-generation TKI.

Zipalertinib plus platinum-based chemotherapy significantly improved progression-free survival at a planned interim analysis of the phase 3 REZILIENT3 trial.

Longer follow-up links ivonescimab plus chemo to stronger survival gains in EGFR-mutant NSCLC worldwide, supporting FDA review after TKI failure.

The phase 3 WU-KONG28 trial found that sunvozertinib decreased disease progression risk by 35% and nearly doubled response rates vs platinum-based chemotherapy in treatment-naive patients with NSCLC harboring EGFR exon 20 insertions.

FDA accepted the NDA for zipalertinib to treat previously treated metastatic NSCLC with EGFR exon 20 insertion mutations. Target action date: 2/27/27.

Phase 3 data show oral sunvozertinib beats platinum chemo in EGFR exon 20ins NSCLC, boosting PFS and responses with tolerable safety.

FDA approves monthly subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced NSCLC, cutting clinic time and infusion reactions while maintaining efficacy.

The FDA reviews ivonescimab for advanced lung cancer treatment, showing promising trial results and potential to enhance patient outcomes post-TKI therapy.

A new study reveals that savolitinib and osimertinib significantly enhance survival in advanced EGFR-mutated lung cancer, outperforming traditional chemotherapy.

A groundbreaking biologics license application for ivonescimab targets advanced lung cancer, promising improved outcomes for patients with EGFR mutations.

Silevertinib shows promising antitumor activity in NSCLC and plans for a phase 2 trial in glioblastoma, targeting unmet oncology needs.

Sevabertinib demonstrates promising safety and efficacy in treating non–small cell lung cancer with HER2 or EGFR mutations, offering hope for patients.

Sacituzumab tirumotecan significantly improves progression-free survival in EGFR-mutated non-small cell lung cancer compared to traditional chemotherapy.

Zipalertinib shows promising efficacy in treating non-small cell lung cancer with CNS metastases, highlighting its potential as a new therapeutic option.

Combining local consolidative therapy with osimertinib enhances progression-free survival in metastatic EGFR-mutant non-small cell lung cancer patients.

During a live event, Shirish M. Gadgeel, MD, discussed different management approaches to the improve tolerability of amivantamab/lazertinib in EGFR-mutated lung cancer.

The FDA designates iza-bren as a breakthrough therapy for advanced EGFR-mutant NSCLC, promising improved outcomes for patients with limited options.